Patents by Inventor Lars Anders Mikael Johansson

Lars Anders Mikael Johansson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and their use
    Patent number: 11970463
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: April 30, 2024
    Assignees: AstraZeneca AB, Mitsubishi Tanabe Pharma Corporation
    Inventors: Lars Anders Mikael Johansson, Giulia Bergonzini, Henrik Gradén, Hiroshi Sugama, Takehiko Matsumura
  • COMPOUNDS AND THEIR USE
    Publication number: 20230110122
    Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 13, 2023
    Inventors: Lars Anders Mikael JOHANSSON, Giulia BERGONZINI, Henrik GRADÉN, Hiroshi SUGAMA, Takehiko MATSUMURA
  • Therapeutic agents
    Patent number: 8685958
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 1, 2014
    Assignee: AstraZeneca AB
    Inventor: Lars Anders Mikael Johansson
  • (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds
    Patent number: 8546375
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: July 5, 2011
    Date of Patent: October 1, 2013
    Assignee: AstraZeneca AB
    Inventors: Susanne Doris Margit Bökman-Winiwarter, Marlene Fredenwall, Carl Anders Hogner, Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Björn Christian Ingvar Löfberg, Sverker Von Unge
  • Therapeutic Agents
    Publication number: 20130184250
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: July 13, 2012
    Publication date: July 18, 2013
    Applicant: ASTRAZENECA AB
    Inventor: Lars Anders Mikael Johansson
  • Therapeutic agents 713
    Patent number: 8110566
    Abstract: Disclosed herein are compounds of formula I in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 7, 2012
    Assignee: AstraZeneca AB
    Inventors: Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Bjorn Christian Ingvar Lofberg, Joachim Persson
  • (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS
    Publication number: 20120010189
    Abstract: Disclosed herein are azetidinyl compounds of formula I, as described herein, pharmaceutical compositions comprising an azetidinyl compound, and a method of using an azetidinyl compound in the treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 12, 2012
    Applicant: AstraZeneca AB
    Inventors: Susanne Doris Margit Bökman-Winiwarter, Marlene FREDENWALL, Carl Anders Hogner, Lars Anders Mikael Johansson, Robert Andrew Judkins, Lanna Li, Björn Christian Ingvar Löfberg, Sverker Von Unge
  • THERAPEUTIC AGENTS 713
    Publication number: 20100280000
    Abstract: Disclosed herein are compounds of formula I in which R1, R2, R3, R4, R5, A, X, Y are as described in the specification, their use in pharmaceutical compositions and in methods of treatment or prophylaxis of a melanin-concentrating hormone related disease or condition.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 4, 2010
    Applicant: AstraZeneca AB
    Inventors: Lars Anders Mikael JOHANSSON, Robert Andrew Judkins, Lanna Li, Bjorn Christian Ingvar Lofberg, Joachim Persson